מדידת ספיגת דופמין בסינפטוזומים במוח עכבר באמצעות דופמין עם תווית רדיו

Executive Industry Relevance

This method enables quantitative assessment of dopamine transporter (DAT) function in a native neuronal membrane environment, supporting target validation for neuropsychiatric drug discovery. By measuring specific versus nonspecific radiolabeled dopamine uptake, it provides mechanistic de-risking for compounds modulating dopaminergic signaling. The assay generates reproducible, concentration-dependent data that inform lead optimization and portfolio prioritization in CNS therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Measures functional DAT activity in intact presynaptic terminals, enabling target engagement assessment.
• Operational Value: Uses radiolabeled dopamine to distinguish specific transporter-mediated uptake from background.
• Predictive Value: Supports hypothesis testing of DAT modulation in disease-relevant mouse models.

Screening & Assay Development

• Assay Readiness: Generates quantitative uptake data across a dilution series for dose-response profiling.
• Reproducibility: Includes reference conditions with DAT inhibitors to isolate specific signal.
• Scalability: Uses microcentrifuge tubes and filtration steps compatible with medium-throughput screening.

Translational & Preclinical Research

• Disease Relevance: Evaluates dopaminergic homeostasis in mouse models of neuropsychiatric disorders.
• Translational Continuity: Connects in vitro uptake measurements to in vivo neurochemical outcomes.
• Risk-Adjusted Decisions: Provides functional biomarker data to support go/no-go criteria in lead identification.

Pipeline & Workflow Integration

The assay fits within the discovery continuum from target validation to lead identification, providing functional readouts that bridge molecular target engagement and phenotypic outcomes in CNS drug discovery.

• Discovery Biology: Tests dopaminergic pathway integrity and transporter function in native synaptosomes.
• Screening: Enables compound screening against DAT using radiolabeled ligand displacement or uptake inhibition.
• Analytics: Generates radioactive counts converted to uptake rates after background subtraction for quantitative comparison.
• Translational Research: Aligns with preclinical biomarker strategies for dopaminergic dysfunction.
• Enterprise Reuse: Establishes a reusable platform for evaluating dopaminergic modulators across multiple projects.

Operational & Enterprise Impact

• Scientific Value: Provides direct measurement of DAT function, reducing mechanistic ambiguity in target validation.
• Operational Value: Standardized protocol with internal controls ensures reproducibility across laboratories.
• Strategic Value: Informs early go/no-go decisions by quantifying target modulation capacity.
• Portfolio Impact: Supports risk-adjusted advancement of CNS candidates with validated dopaminergic mechanism.

Implementation Considerations

• Requires expertise in radioligand handling and scintillation counting.
• Dependent on access to tritiated dopamine and scintillation counters.
• Needs standardization of synaptosome preparation and protein normalization.
• Adaptation to other neurotransmitter systems requires validation of ligands and inhibitors.
• Background signal correction is essential for accurate uptake quantification.

Biopharma FAQs